In conclusion, this study provides convincing evidence supporting a role of NLRP3 inflammasome complex as regulatory hub linking EGCs and intestinal epithelial cells, taking a relevant part in the pathophysiological mechanisms underlying the mucosal barrier alterations associated with obesity (Figure 7F). Based on this evidence, enteric glial NLRP3 inflammasome might represent an interesting molecular target for the development of novel pharmacological approaches aimed at managing the enteric inflammation and intestinal mucosal dysfunctions associated with obesity. The gene discussed is NLRP3; the disease is obesity disorder.